Endogenous and Exogenous Natural Adjuvants for Vaccine Development

Bolhassani, Azam; Talebi, Somayeh; Anvar, Ali

doi:10.2174/1389557517666170228115801

Cited by 17 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite mentioned advantages of MEVs, poor immunogenicity is considered as a major drawback to development of MEVs [14][15][16]. To overcome the mentioned blind spot use of some natural protein-based adjuvants such as diphtheria toxin (DT), cholera toxin B-subunit (CTxB), heat-labile enterotoxin B subunit (LTB) and toll-like receptors (TLRs) ligands in final construct of proposed vaccines is suggested [17][18][19]. In the study, CTxB and LT-IIc were selected as protein adjuvants.…”

Section: Introductionmentioning

confidence: 99%

Towards the first multi-epitope recombinant vaccine against Crimean-Congo hemorrhagic fever virus: A computer-aided vaccine design approach

Nosrati

Behbahani

Mohabatkar

2019

Journal of Biomedical Informatics

View full text Add to dashboard Cite

A R T I C L E I N F O Keywords:Crimean-Congo hemorrhagic fever Computer-aided vaccine design Multi-epitope vaccine A B S T R A C T Crimean-Congo hemorrhagic fever (CCHF) is considered one of the major public health concerns with case fatality rates of up to 80%. Currently, there is no effective approved vaccine for CCHF. In this study, we used a computer-aided vaccine design approach to develop the first multi-epitope recombinant vaccine for CCHF. For this purpose, linear B-cell and T-cell binding epitopes from two structural glycoproteins of CCHF virus including Gc and Gn were predicted. The epitopes were further studied regarding their antigenicity, allergenicity, hydrophobicity, stability, toxicity and population coverage. A total number of seven epitopes including five T-cell and two B-cell epitopes were screened for the final vaccine construct. Final vaccine construct composed of 382 amino acid residues which were organized in four domains including linear B-cell, T-cell epitopes and cholera toxin B-subunit (CTxB) along with heat labile enterotoxin IIc B subunit (LT-IIc) as adjuvants. All the segments were joined using appropriate linkers. The physicochemical properties as well as the presence of IFN-γ inducing epitopes in the proposed vaccine, was also checked to determining the vaccine stability, solubility and its ability to induce cell-mediated immune responses. The 3D structure of proposed vaccine was subjected to the prediction of computational B-cell epitopes and molecular docking studies with MHC-I and II molecules. Furthermore, molecular dynamics stimulations were performed to study the vaccine-MHCs complexes stability during stimulation time. The results suggest that our proposed vaccine was stable, well soluble in water and potentially antigenic. Results also demonstrated that the vaccine can induce both humoral and cell-mediated immune responses and could serve as a promising anti-CCHF vaccine candidate.

show abstract

Section: Introductionmentioning

confidence: 99%

Towards the first multi-epitope recombinant vaccine against Crimean-Congo hemorrhagic fever virus: A computer-aided vaccine design approach

Nosrati

Behbahani

Mohabatkar

2019

Journal of Biomedical Informatics

View full text Add to dashboard Cite

show abstract

“…In addition, some Chinese herbal medicinal polysaccharides have been used as safe and effective adjuvants [ 77 , 107 , 112 , 113 ]. APS as an adjuvant combined with influenza vaccine can improve the immune response and systemic humoral response to H5N1 virus infection [ 46 , 114 ]. APS can potentially be used as an immunomodulator for a foot-and-mouth disease virus (FMDV), which is an RNA virus vaccine, and provide better protection against FMDV [ 115 ].…”

Section: Polysaccharide Adjuvant For Antiviral Vaccinementioning

confidence: 99%

Application prospect of polysaccharides in the development of anti-novel coronavirus drugs and vaccines

Chen¹,

Han²,

Wang

2020

International Journal of Biological Macromolecules

130

113

View full text Add to dashboard Cite

Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, it has spread rapidly worldwide and poses a great threat to public health. This is the third serious coronavirus outbreak in <20 years, following SARS in 2002–2003 and MERS in 2012. So far, there are almost no specific clinically effective drugs and vaccines available for COVID-19. Polysaccharides with good safety, immune regulation and antiviral activity have broad application prospects in anti-virus, especially in anti-coronavirus applications. Here, we reviewed the antiviral mechanisms of some polysaccharides, such as glycosaminoglycans, marine polysaccharides, traditional Chinese medicine polysaccharides, and their application progress in anti-coronavirus. In particular, the application prospects of polysaccharide-based vaccine adjuvants, nanomaterials and drug delivery systems in the fight against novel coronavirus were also analyzed and summarized. Additionally, we speculate the possible mechanisms of polysaccharides anti-SARS-CoV-2, and propose the strategy of loading S or N protein from coronavirus onto polysaccharide capped gold nanoparticles vaccine for COVID-19 treatment. This review may provide a new approach for the development of COVID-19 therapeutic agents and vaccines.

show abstract

“…Not by accident, some of the polysaccharides above ( Chitosan , Astragalus spp. polysaccharides, Carrageenan , and Alginate ) are proposed by many authors as potent vaccine adjuvants to improve immune response [ 170 , 176 , 177 , 178 , 179 , 180 ].…”

Section: Prevention and Prophylaxis Of Rti’smentioning

confidence: 99%

Advances in the Prophylaxis of Respiratory Infections by the Nasal and the Oromucosal Route: Relevance to the Fight with the SARS-CoV-2 Pandemic

et al. 2022

View full text Add to dashboard Cite

In this time of COVID-19 pandemic, the strategies for prevention of the infection are a primary concern. Looking more globally on the subject and acknowledging the high degree of misuse of protective face masks from the population, we focused this review on alternative pharmaceutical developments eligible for self-defense against respiratory infections. In particular, the attention herein is directed to the nasal and oromucosal formulations intended to boost the local immunity, neutralize or mechanically “trap” the pathogens at the site of entry (nose or mouth). The current work presents a critical review of the contemporary methods of immune- and chemoprophylaxis and their suitability and applicability in topical mucosal dosage forms for SARS-CoV-2 prophylaxis.

show abstract

Endogenous and Exogenous Natural Adjuvants for Vaccine Development

Abstract: In this review, the immune activities of the natural adjuvants especially endogenous adjuvants and their mechanisms of action are discussed.

Cited by 17 publications

References 0 publications

Towards the first multi-epitope recombinant vaccine against Crimean-Congo hemorrhagic fever virus: A computer-aided vaccine design approach

Towards the first multi-epitope recombinant vaccine against Crimean-Congo hemorrhagic fever virus: A computer-aided vaccine design approach

Application prospect of polysaccharides in the development of anti-novel coronavirus drugs and vaccines

Advances in the Prophylaxis of Respiratory Infections by the Nasal and the Oromucosal Route: Relevance to the Fight with the SARS-CoV-2 Pandemic

Contact Info

Product

Resources

About